56.60 -0.35 (-0.61%)
Pre-market: 8:00AM EST
|Bid||56.48 x 200|
|Ask||56.68 x 100|
|Day's range||56.65 - 57.37|
|52-week range||53.63 - 66.80|
|PE ratio (TTM)||55.09|
|Earnings date||2 Feb 2018|
|Forward dividend & yield||1.92 (3.46%)|
|1y target est||65.36|
Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.
Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year. In the meantime, Roche Holding AG has shaken up Wall Street expectations for the $15-billion (£11.3 billion) lung cancer market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments.
Merck , known as MSD outside the United States and Canada, today announced findings from the phase 2 KEYNOTE-170 trial investigating the use of KEYTRUDA® , the company’s anti-PD-1 therapy, in the cohort of patients with relapsed or refractory primary mediastinal large B-cell lymphoma , a type of non-Hodgkin lymphoma.
Tecentriq, whose sales pale compared to established immunotherapies from Bristol-Myers Squibb and Merck & Co Inc, is a pillar of Roche's plan to replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose expiring patents have exposed them to cheaper competition. As a consequence, Roche is seeking to expand indications and patients eligible for treatment with its drug, which analysts see topping $4.6 billion in annual sales by 2023.
Merck & Co., Inc. , known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine has published online the main results from the pivotal Phase 3 clinical study of PREVYMIS™ , the company’s new medicine for prophylaxis of cytomegalovirus infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant .
Wall Street analysts estimate Merck & Co.’s (MRK) top line to rise 1.1% to ~$40.2 billion in 2017. EPS (earnings per share) is expected to be $3.94 for 2017.
Pepsi is a fantastic business with a healthy dividend. But your quarterly check will be even larger if you invest in these three companies.
Merck, a leading science and technology company, today announced the FDA 510(K) clearance of the benchtop embryo incubator Geri™. This innovative technology, designed to improve processes in fertility laboratories, will be commercially available to IVF clinics in the U.S. in the first half of 2018.
In 3Q17, Merck's Remicade revenues fell ~31% to $214 million compared to $311 million in 3Q16. The fall was driven by lower sales due to generic competition and biosimilars.
In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.
The combined revenues of Merck's (MRK) Januvia and Janumet in 3Q17 was $1.52 billion, a 2% decline compared to $1.55 billion in 3Q16, mainly due to lower sales of Janumet.
Bristol-Myers' (BMY) phase III study evaluating Opdivo versus docetaxel was stopped earlier than expected as it met the primary endpoint.
LONDON/FRANKFURT (Reuters) - Swiss food giant Nestle (NESN.S) and the private equity owners of German drug firm Stada (STAGn.DE) are both preparing tentative bids for Merck KgaA's (MRCG.DE) consumer health unit, several sources told Reuters. Merck's financial adviser JPMorgan has invited bids for the business, which is valued at about 4 billion euros (£3.5 billion), ahead of a Dec. 15 deadline, the sources said. Nestle is widely seen as a natural buyer for the maker of Seven Seas vitamins and Bion nutritional supplements, after previous talks to set up a consumer joint venture with Merck fell through over the summer.
Merck & Co.'s (MRK) Gardasil franchise reported total sales of $675 million in3Q17, a 22% fall compared to $860 million in 3Q16.
For 3Q17, the Pharmaceutical segment contributed ~88.7% of Merck's total revenues, reporting revenues of $9.2 billion in 3Q17, a 3% fall from $9.4 billion in 3Q16.
Merck & Co. (MRK) reported EPS of $1.11 on revenues of $10.3 billion in 3Q17, which was a 2% fall compared to EPS of $1.07 on revenues of $10.5 billion in 3Q16.